Tag: ZYDUS CADILA

HOME » ZYDUS CADILA
» 2019-04-18

Pharmaceutical manufacturer Zydus Cadila announced phase-III trials of the Desidustat, an investigational new drug and a Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase (PH) enzyme inhibitor used for the treatment of anemia […]

» 2019-04-08

Pharmaceutical manufacturer Zydus Cadila said that it received tentative approval from the US Food and Drug Administration for sales of a generic equivalent of UCB Inc’s Vimpat tablets. A tentative […]

» 2019-04-02

Pharmaceutical manufacturer Zydus Cadila said that it has received tentative approval from the US Food and Drug Administration for sales of mirabegron extended-release tablets. A tentative approval means that the […]

» 2019-03-29

Pharmaceutical manufacturer Zydus Cadila said that it has received approval from the United States Food and Drug Administration for the sales of a generic equivalent of Gilead Sciences’ hypertension drug […]

» 2019-03-27

Indian pharmaceutical manufacturers Lupin, Unichem Laboratories and Alembic Pharmaceuticals said that they has received approval from the United States Food and Drug Administration to sell generic versions of Eli Lilly’s […]

» 2019-03-22

Pharmaceutical manufacturer Zydus Cadila said it received final approval from the United States Food and Drug Administration for sales of a generic version of Sunovion Pharmaceuticals’ Latuda tablets. Lurasidone tablets […]

» 2019-03-19

Pharmaceutical manufacturer Zydus Cadila said that it received final approval from the United States Food and Drug Administration for the sale of a generic version of Valeant’s Zovirax ointment. Acyclovir, […]

» 2019-03-14

Pharmaceutical manufacturer Zydus Cadila said it received tentative approval from the US Food and Administration for the sales of of Sitagliptin and Metformin oral diabetes tablets that help control blood […]

» 2019-03-13

Pharmaceutical manufacturer Zydus Cadila said it received final approval from the US Food and Drug Administration for the sales of Potassium Chloride extended-release tablets for the treatment of various diseases […]

» 2019-03-12

Pharmaceutical manufacturer Zydus Cadila said it received final approval from the US Food and Drug Administration to launch Atenolol and Chlorthalidone tablets to treat hypertension and chest pain. The company […]

» 2018-10-24

Zydus Wellness, the consumer healthcare arm of Zydus Cadila, said it has agreed to acquire Heinz India Private Ltd, the Indian unit of global FMCG major Kraft Heinz. The transaction, which will […]

» 2018-08-30

Zydus Cadila said it received the final approval from the USFDA to market cholesterol-lowering Gemfibrozil and antipsychotic Aripiprazole in the US. Gemfibrozil Tablets are used together with diet to treat […]

» 2018-07-20

Zydus Cadila said it received the final approval from the USFDA to sell Spironolactone Tablets, used to treat blood pressure and heart failure. The tablets, in strengths of 25 mg, […]

» 2018-07-07

Zydus Cadila said it has received tentative regulatory approval from the US Food & Drug Administration for selling Deferasirox, used to chelate or expel excess iron from the blood. The […]

» 2018-06-19

Zydus Cadila, one of India’s largest drug makers, said it has received tentative approval to market tadalafil, the generic ingredient of the most popular erectile dysfunction drug Cialis, in the […]

» 2018-06-06

Pharmaceuticals maker Zydus Cadila said the USFDA has completed an inspection of its injectables manufacturing plant at Ahmedabad with zero observations. No observations is good news for pharma manufacturers as […]

» 2018-05-28

Pharma giant Zydus Cadila said it received final approval from the US Food and Drug Administration to sell a skin ointment and an ulcer tablet in the country. Ointment Nystatin […]

» 2018-05-02

Zydus Cadila, one of India’s largest pharmaceuticals manufacturers, said it got the the final approval from the US Food and Drug Administration to market Bumetanide, used to treat swelling. The […]

» 2018-04-19

Pharmaceuticals maker Zydus Cadila said it received the final approval from the USFDA to market inflammation solution Diclofenac Sodium in the country. Diclofenac Sodium topical solution, 1.5%, is a non-steroidal […]

» 2018-01-04

Glenmark Pharmaceuticals said it has launched a biosimilar of Adalimumab, a drug for Plaque Psoriasis and Rheumatoid Arthritis from Cadila Healthcare Ltd.. “The launch of ADALY marks the launch of […]